Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Tahrani, Abd A., Barnett, Anthony H., Bailey, Clifford J.·2016·Nature Reviews Endocrinology
DOI 10.1038/nrendo.2016.86

Cites (362)

Items 201–362 of 362

  1. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    André Jacques Scheen, Guillaume Charpentier, Carl Johan Östgren, Åsa Hellqvist, Ingrid A. M. Gause‐Nilsson · 2010 · Diabetes/Metabolism Research and Reviews
  2. Beneficial effects of metformin on haemostasis and vascular function in man
    Peter J. Grant · 2003 · Diabetes & Metabolism
  3. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
    Potts, Jessica E., Gray, Laura J., Brady, Emer M., Khunti, Kamlesh, Davies, Melanie J., Bodicoat, Danielle H. · 2015 · PLOS ONE
  4. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
    Wenying Yang, Jie Liu, Zhongyan Shan, Haoming Tian, Zhiguang Zhou, Qiuhe Ji, Jianping Weng, Weiping Jia, Juming Lu, Jing Liu et al. · 2013 · The Lancet Diabetes & Endocrinology
  5. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
    Jacob Allen Udell, Deepak L. Bhatt, Eugene Braunwald, Matthew Aaron Cavender, Ofri Mosenzon, Philippe Gabríel Steg, Jaime A. Davidson, José Carlos Nicolau, Ramon L. Corbalan, Boaz Hirshberg et al. · 2014 · Diabetes Care
  6. Results of a reevaluation of cardiovascular outcomes in the RECORD trial
    Kenneth W. Mahaffey, Gail E. Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer A. White, Laura Kristin Newby, Michel Komajda N, John J.V. McMurray, Robert Bigelow et al. · 2013 · American Heart Journal
  7. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
    Juan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, Hua Guo, Gregory T. Golm, Christine McCrary Sisk, Keith D. Kaufman, Barry J. Goldstein · 2012 · Diabetes Care
  8. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
    J. R. Lindsay, N. A. Duffy, Aine M. McKillop, J. E. S. Ardill, Finbarr P.M. O'Harte, Peter R. Flatt, Patrick M Bell · 2005 · Diabetic Medicine
  9. Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell
    Mulherin AJ, Amy Oh, Helena Kim, Anthony J. Grieco, Lina M. Lauffer, Patricia Lee Brubaker · 2011 · Endocrinology
  10. Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial
    Robert E. Ratner, Julio Rosenstock, G. Boka, on behalf of the DRI6012 Study Investigators · 2010 · Diabetic Medicine
  11. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
    Michaëla Diamant, Luc Van Gaal, Bruno Guerci, Stephen N. Stranks, Jenny Han, Jaret L. Malloy, Marilyn K Boardman, MICHAEL E. TRAUTMANN · 2014 · The Lancet Diabetes & Endocrinology
  12. Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( AWARD ‐5): a randomized, phase III study
    Ruth S. Weinstock, Bruno Guerci, Guillermo E. Umpierrez, Michael Albrecht Nauck, Zachary Skrivanek, Zvonko Miličević · 2015 · Diabetes Obesity and Metabolism
  13. A Comparison of Efficacy and Safety of Vildagliptin and Gliclazide in Combination with Metformin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A 52-week, Randomized Study
    CLAUDIA M. FILOZOF, Jean–François Gautier · 2009 · Diabetic Medicine
  14. Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
    Keith C. Ferdinand, William B. White, David A. Calhoun, Eva Lonn, Philip T. Sager, Rocco L. Brunelle, Honghua H. Jiang, Rebecca J. Threlkeld, Kenneth E. Robertson, Mary Jane Geiger · 2014 · Hypertension
  15. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
    Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., Hanefeld, M. · 2014 · Diabetic Medicine
  16. Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
    Elizabeth S. Mearns, Diana M Sobieraj, Charles Michael White, Whitney J Saulsberry, Christine G. Kohn, Yunes Doleh, E. Zaccaro, Craig Ian Coleman · 2015 · PLoS ONE
  17. Dipeptidylpeptitase-4 Inhibitors (Gliptins)
    André Jacques Scheen · 2010 · Clinical Pharmacokinetics
  18. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study
    Szu‐Chun Hung, Yu‐Kang Chang, Jia‐Sin Liu, Ko‐Lin Kuo, Yu‐Hsin Chen, Chih-Cheng Hsu, Der‐Cherng Tarng · 2015 · The Lancet Diabetes & Endocrinology
  19. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial
    Nauck, Michael, Rizzo, Manfredi, Johnson, Andrew, Bosch-Traberg, Heidrun, Madsen, Jesper, Cariou, Bertrand · 2016 · Diabetes Care
  20. Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
    M. Katout, Hong Zhu, Jessica Rutsky, P. Shah, Robert D. Brook, Jixin Zhong, Sanjay Rajagopalan · 2013 · American Journal of Hypertension
  21. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P)
    M. Pinget, Ronald Goldenberg, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Hailing Guo, Ronnie Aronson · 2013 · Diabetes Obesity and Metabolism
  22. State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
    Rodolfo Guardado‐Mendoza, Annamaria Prioletta, Lilia M. Jiménez-Ceja, Aravind Sosale, Franco B. Folli · 2013 · Archives of Medical Science
  23. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
    Paul Nyirjesy, Jack D. Sobel, Albert Fung, Cristiana Mayer, George A. Capuano, Kirk Ways, Keith Usiskin · 2014 · Current Medical Research and Opinion
  24. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
    Tahrani, A A, Varughese, G I, Scarpello, J H, Hanna, F W F · 2007 · BMJ
  25. Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
    Masanori Abe, Kazuyoshi Okada, Masayoshi Soma · 2011 · Current Drug Metabolism
  26. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes
    Anthony H. Cincotta, ALBERT H. MEIER, M. Cincotta · 1999 · Expert Opinion on Investigational Drugs
  27. The target of metformin in type 2 diabetes
    Ferrannini, Ele · 2014 · New England Journal of Medicine
  28. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
    Peter N. Weissman, Molly C. Carr, June Ye, Deborah T. Cirkel, Murray W Stewart, Caroline Perry, Richard E. Pratley · 2014 · Diabetologia
  29. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
    Anne M. Gill, Byron J. Hoogwerf, Jude Burger, SIMON R. BRUCE, Leigh MacConell, Ping Yan, Daniel K. Braun, Joseph M. Giaconia, James K. Malone · 2010 · Cardiovascular Diabetology
  30. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
    Simonsen, L., Holst, J. J., Deacon, C. F. · 2006 · Diabetologia
  31. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis
    Billington, Emma O., Grey, Andrew, Bolland, Mark J. · 2015 · Diabetologia
  32. Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
    Juan Camilo Arjona Ferreira, Dalila B. Corry, Carl Erik Mogensen, Lance Alan Sloan, Lei Xu, Gregory T. Golm, Edward J. Gonzalez, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein · 2013 · American Journal of Kidney Diseases
  33. Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
    Fonseca, Vivian A., Handelsman, Yehuda, Staels, Bart · 2010 · Diabetes, Obesity and Metabolism
  34. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-s)
    Rosenstock, Julio, Hanefeld, Markolf, Shamanna, Paramesh, Min, Kyung Wan, Boka, Gabor, Miossec, Patrick, Zhou, Tianyue, Muehlen-Bartmer, Isabel, Ratner, Robert E. · 2014 · Journal of Diabetes and its Complications
  35. Gut peptides and type 2 diabetes mellitus treatment
    Bo Åhrén · 2003 · Current Diabetes Reports
  36. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
    Edoardo Mannucci, Federica Tesi, Gianluca Bardini, Agostino Ognibene, Petracca Mg, S Ciani, Anna Pezzatini, Marco Brogi, Ilaria Dicembrini, Francesco Cremasco et al. · 2004 · PubMed
  37. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    S Hu, Shuya Wang, B Fanelli, P A Bell, B. E. Dunning, Sabine Geisse, R Schmitz, Brian R. Boettcher · 2000 · PubMed
  38. One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
    Stephen C. L. Gough, Bruce W. Bode, Vincent C. Woo, Helena W. Rodbard, Sultan Linjawi, Mette Zacho, P. D. Reiter, John B. Buse · 2015 · Diabetes Obesity and Metabolism
  39. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
    Xuping Yang, Dan Lai, Xiaoyan Zhong, Hongping Shen, Yilan Huang · 2014 · European Journal of Clinical Pharmacology
  40. Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
    Agata Ptaszynska, Kristina M. Johnsson, Shamik J. Parikh, Tjerk WA de Bruin, Anne Marie Apanovitch, James F. List · 2014 · Drug Safety
  41. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
    Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., Hardy, T. A. · 2011 · Diabetes, Obesity and Metabolism
  42. The Pharmacogenetics of Type 2 Diabetes: A Systematic Review
    Nisa M. Maruthur, Matthew O. Gribble, Wendy L. Bennett, Shari Danielle Bolen, Lisa M Wilson, Poojitha Balakrishnan, Anita Sahu, Eric B Bass, W.H. Linda Kao, Jeanne M. Clark · 2014 · Diabetes Care
  43. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
    Michael Albrecht Nauck, Stefano Del Prato, Santiago Durán-Garcia, Katja Rohwedder, Anna Maria Langkilde, Jennifer E. Sugg, Shamik J. Parikh · 2014 · Diabetes Obesity and Metabolism
  44. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
    Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Péter Stella, Hans‐Juergen Woerle, Uli C. Broedl · 2015 · Clinical Therapeutics
  45. Incretin hormone mimetics and analogues in diabetes therapeutics
    Brian D. Green, Peter R. Flatt · 2007 · Best Practice & Research Clinical Endocrinology & Metabolism
  46. Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
    Jane E.B. Reusch, Murray W Stewart, C. M. Perkins, Deborah T. Cirkel, J. Ye, Caroline Perry, Robert Reinhardt, Bruce W. Bode · 2014 · Diabetes Obesity and Metabolism
  47. Bromocriptine: old drug, new formulation and new indication
    Richard I. G. Holt, Anthony H Barnett, Clifford J. Bailey · 2010 · Diabetes Obesity and Metabolism
  48. CNS Regulation of Glucose Homeostasis
    Carol Lam, Madhu Chari, Tony K.T. Lam · 2009 · Physiology
  49. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)
    Barnett, A. H., Krentz, A. J., Strojek, K., Sieradzki, J., Azizi, F., Embong, M., Imamoglu, S., Perušičová, J., Uličiansky, V., Winkler, G. · 2008 · Diabetes, Obesity and Metabolism
  50. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
    Andrew Ahmann, Helena W. Rodbard, Julio Rosenstock, Jorma T. Lahtela, Luis De Loredo, Karen Tornøe, A. Boopalan, Michael Albrecht Nauck, on behalf of the NN2211‐3917 Study Group · 2015 · Diabetes Obesity and Metabolism
  51. Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
    James Edward Foley, SK Sreenan · 2009 · Hormone and Metabolic Research
  52. Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension
    Karl Winkler, Thomas Konrad, S. Füllert, I. Friedrich, Ramadan Destani, Manfred W. Baumstark, Kristin Krebs, Heinrich Wieland, Winfried März · 2003 · Diabetes Care
  53. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Abd A. Tahrani, Milan K. Piya, Anthony H Barnett · 2009 · Advances in Therapy
  54. Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus
    Yanling He, Denise B. Serra, Yibin Wang, Joelle Campestrini, Gilles‐Jacques Rivière, Carolyn Fiona Deacon, Jens Juul Holst, Sherwyn Leon Schwartz, Jace C. Nielsen, Monica Ligueros‐Saylan · 2007 · Clinical Pharmacokinetics
  55. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
    Clifford J. Bailey · 2015 · Clinical Pharmacology & Therapeutics
  56. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
    Philip Home, Paramesh Shamanna, Murray W Stewart, Fang Yang, Michael J. Miller, Caroline Perry, Molly C. Carr · 2014 · Diabetes Obesity and Metabolism
  57. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
    Haesuk Park, Chanhyun Park, Yoona A. Kim, Karen L. Rascati · 2012 · Annals of Pharmacotherapy
  58. Investigation of Exenatide Elimination and Its In Vivo and In Vitro Degradation
    Kathrin Copley, Kevin M. McCowen, Richard Hiles, Loretta L. Nielsen, Andrew John Young, David G. Parkes · 2006 · Current Drug Metabolism
  59. Pramlintide and the treatment of diabetes: a review of the data since its introduction
    Lisa M. Younk, Maia Mikeladze, Stephen N. Davis · 2011 · Expert Opinion on Pharmacotherapy
  60. Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
    Johan Farngren, Margaretha Persson, Anja Schweizer, James Edward Foley, Bo Åhrén · 2012 · The Journal of Clinical Endocrinology & Metabolism
  61. Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
    Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M. et al. · 2016 · Diabetes, Obesity and Metabolism
  62. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
    Y. M. Cho, Timothy J. Kieffer · 2010 · Diabetologia
  63. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
    Scheen, André J · 2013 · Expert Opinion on Drug Metabolism & Toxicology
  64. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
    Nobuya Inagaki, Hitoshi Onouchi, Hideaki Maezawa, Shingo Kuroda, Kohei Kaku · 2015 · The Lancet Diabetes & Endocrinology
  65. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
    Michael Albrecht Nauck, Andrea El-Ouaghlidi · 2005 · Diabetologia
  66. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.
    Espen Jimenez‐Solem, Mette H Rasmussen, Mikkel Christensen, Filip Krag Knop · 2010 · PubMed
  67. Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner
    Maayan Barnea, Liyan Haviv, Roee Gutman, Nava Chapnik, Zecharia Madar, Oren Froy · 2012 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  68. Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production
    Yang, Clair S., Lam, Carol K.L., Chari, Madhu, Cheung, Grace W.C., Kokorovic, Andrea, Gao, Sun, Leclerc, Isabelle, Rutter, Guy A., Lam, Tony K.T. · 2010 · Diabetes
  69. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
    Paul Arnouts, Davide Bolignano, Ionuţ Nistor, Henk J. G. Bilo, Luigi Gnudi, James Goya Heaf, Wim Van Biesen · 2013 · Nephrology Dialysis Transplantation
  70. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study
    Julio Rosenstock, C. Wilson, Penny R. Fleck · 2013 · Diabetes Obesity and Metabolism
  71. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
    Schwartz, Ann V., Chen, Haiying, Ambrosius, Walter T., Sood, Ajay, Josse, Robert G., Bonds, Denise E., Schnall, Adrian M., Vittinghoff, Eric, Bauer, Douglas C., Banerji, Mary Ann et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism
  72. Empagliflozin as add‐on to metformin in people with Type 2 diabetes
    Ludwig Merker, H.-U. Häring, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gu-Hwan Kim, Thomas W. Meinicke, H.J. Woerle, Uli C. Broedl, the EMPA‐REG EXTEND MET investigators · 2015 · Diabetic Medicine
  73. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
    Davies, Melanie, Heller, Simon, Sreenan, Seamus, Sapin, Hélène, Adetunji, Omolara, Tahbaz, Arash, Vora, Jiten · 2013 · Diabetes Care
  74. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
    John B. Buse, Helena W. Rodbard, Carlos Trescolí Serrano, Junxiang Luo, T. Iványi, Juliana M. Bue‐Valleskey, Mark L. Hartman, Michelle A. Carey, Annette M. Chang · 2015 · Diabetes Care
  75. Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
    André Jacques Scheen · 2014 · Clinical Pharmacokinetics
  76. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Hans-Ulrich Haering, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Thomas W. Meinicke, Hans Juergen Woerle, Uli C. Broedl · 2015 · Diabetes Research and Clinical Practice
  77. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
    Anthony H Barnett · 2011 · Core evidence
  78. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study
    Sten Madsbad, Bente K. Kilhovd, I. Lager, Pertti Mustajoki, A. Dejgaard, for the Scandinavian Repaglinide Group · 2001 · Diabetic Medicine
  79. Exenatide
    Barnett, A · 2007 · Expert Opinion on Pharmacotherapy
  80. Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide
    A J Scheen · 2007 · Clinical Pharmacokinetics
  81. ß‐cell function and anti‐diabetic pharmacotherapy
    Stefano Del Prato, Cristina Bianchi, Piero Marchetti · 2007 · Diabetes/Metabolism Research and Reviews
  82. Impact of Improved Glycemic Control on Quality of Life in Patients with Diabetes
    Alan M. Jacobson · 2004 · Endocrine Practice
  83. Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide
    Hu, Shiling, Wang, Shuya, Fanelli, Barbara, Bell, Philip A., Dunning, Beth E., Geisse, Sabine, Schmitz, Rita, Boettcher, Brian R. · 2000 · The Journal of Pharmacology and Experimental Therapeutics
  84. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
    Katherine Esposito, Paolo Chiodini, Maria Ida Maiorino, Annalisa Capuano, Domenico Cozzolino, Michela Petrizzo, Giuseppe Bellastella, Dario Giugliano · 2015 · BMJ Open
  85. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
    Yu-nan Sun, Yi Zhou, Xi Chen, Weng-si Che, Siu-wai Leung · 2014 · BMJ Open
  86. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
    David R. Owens, L. Monnier, Geremia B. Bolli · 2013 · Diabetes & Metabolism
  87. The Islets of Langerhans
    Md. Shahidul Islam · 2010 · Advances in experimental medicine and biology
  88. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
    Mikkel Christensen, Filip Krag Knop, Jens Juul Holst, Tina Vilsbøll · 2009 · PubMed
  89. Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients ( AWARD ‐5)
    Zachary Skrivanek, Brenda L. Gaydos, Jenny Y. Chien, M. J. Geiger, Michael A. Heathman, Scott M. Berry, J. H. Anderson, Thomas M. Forst, Zvonko Miličević, Donald A. Berry · 2014 · Diabetes Obesity and Metabolism
  90. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?
    J. C. Henquin · 1992 · Diabetologia
  91. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double‐blind, placebo‐controlled, 24‐week trial (GetGoal‐M‐Asia)
    Chang Yu Pan, Ping Han, Xiaoming Liu, Shengli Yan, Ping Feng, Zhiguang Zhou, Xiaofeng Lv, Hui Tian, Yang Jin Kui, Benli Su et al. · 2014 · Diabetes/Metabolism Research and Reviews
  92. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
    Carlo Bruno Giorda, Carlotta Sacerdote, Elisa Nada, Lisa Marafetti, Ileana Baldi, Roberto Gnavi · 2014 · Endocrine
  93. Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
    Neeta B. Amin, Xiaoxing Wang, S. M. Jain, D. S. Lee, Gianluca Nucci, James M. Rusnak · 2015 · Diabetes Obesity and Metabolism
  94. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
    Katherine Esposito, Paolo Chiodini, Maria Ida Maiorino, Giuseppe Bellastella, Annalisa Capuano, Dario Giugliano · 2014 · BMJ Open
  95. Trelagliptin: First Global Approval
    Kate McKeage · 2015 · Drugs
  96. Head‐to‐head comparison of dipeptidyl peptidase‐IV inhibitors and sulfonylureas – a meta‐analysis from randomized clinical trials
    Yifei Zhang, Jie Hong, Jie Chi, Weiqiong Gu, Guang Ning, Weiqing Wang · 2013 · Diabetes/Metabolism Research and Reviews
  97. Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
    Julio Rosenstock, Sylvia K Shenouda, Richard M. Bergenstal, John B. Buse, Leonard C. Glass, Cory R. Heilmann, Anita Y. M. Kwan, Leigh MacConell, Byron J. Hoogwerf · 2012 · Diabetes Care
  98. Novel therapeutics for type 2 diabetes: insulin resistance
    Q.A. Altaf, Anthony H Barnett, Abd A. Tahrani · 2014 · Diabetes Obesity and Metabolism
  99. The β-Cell in Human Type 2 Diabetes
    Piero Marchetti, Roberto Lupi, Silvia Del Guerra, Marco Bugliani, Lorella Marselli, Ugo Boggi · 2010 · Advances in experimental medicine and biology
  100. Pharmacokinetic Interactions with Thiazolidinediones
    A J Scheen · 2007 · Clinical Pharmacokinetics
  101. Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies
    T. Wang, F. Wang, Zhuoyue Gou, Huilin Tang, C. Li, Lang Shi, Suodi Zhai · 2014 · Diabetes Obesity and Metabolism
  102. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
    Heike Zimdahl, Carina Ittrich, Ulrike Graefe‐Mody, Bernhard Otto Boehm, Michael Mark, Hans‐Juergen Woerle, Klaus A. Dugi · 2014 · Diabetologia
  103. Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
    Amin, N. B., Wang, X., Mitchell, J. R., Lee, D. S., Nucci, G., Rusnak, J. M. · 2015 · Diabetes, Obesity and Metabolism
  104. Omarigliptin: First Global Approval
    Celeste B. Burness · 2015 · Drugs
  105. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Kira B. Harris, Delilah J. McCarty · 2014 · Therapeutic Advances in Endocrinology and Metabolism
  106. Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials
    Thomas Karagiannis, Aris Liakos, Eleni Bekiari, Eleni A. Athanasiadou, Paschalis Paschos, Despoina Vasilakou, Maria Mainou, Maria Rika, Panagiota Boura, David Richard Matthews et al. · 2015 · Diabetes Obesity and Metabolism
  107. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
    Rury R. Holman, Mary Angelyn Bethel, Juliana C.N. Chan, Jean‐Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel C. Gerstein, Yong Huo, John J.V. McMurray, Lars Rydén et al. · 2014 · American Heart Journal
  108. Five-Year Efficacy and Safety Data of Exenatide Once Weekly
    Carol Wysham, Leigh MacConell, David G. Maggs, Ming Zhou, Peter S. Griffin, MICHAEL E. TRAUTMANN · 2015 · Mayo Clinic Proceedings
  109. Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
    Robert R. Henry, John B. Buse, Giorgio Sesti, Melanie Jane Davies, Klaus H. Jensen, Jason Brett, Richard E. Pratley · 2011 · Endocrine Practice
  110. New treatments in type 2 diabetes: a focus on the incretin‐based therapies
    Anthony H Barnett · 2008 · Clinical Endocrinology
  111. Metformin in Chronic Kidney Disease: Time for a Rethink
    James Goya Heaf · 2014 · Peritoneal Dialysis International
  112. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
    Sri Harsha Tella, Marc Rendell · 2015 · Therapeutic Advances in Endocrinology and Metabolism
  113. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
    Bernard H. Charbonnel, Monica Bertolini, Francisco José Tinahones, Manel Puig‐Domingo, Melanie Jane Davies · 2014 · Journal of Diabetes and its Complications
  114. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial
    Peter Stein, Jolene Kay Berg, Linda Morrow, David Polidori, Eunice Artis, Sarah Rusch, Nicole M. Vaccaro, Damayanthi Devineni · 2014 · Metabolism
  115. Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
    Mikkel Christensen, Filip Krag Knop · 2010 · Current Diabetes Reports
  116. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study
    Robert R. Henry, ERIC J. KLEIN, Jenny Han, Nayyar Iqbal · 2016 · Diabetes Technology & Therapeutics
  117. Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
    Susan Grandy, M. Hashemi, AM Langkilde, Shamik J. Parikh, C. David Sjöström · 2014 · Diabetes Obesity and Metabolism
  118. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis
    Sun, Feng, Wu, Shanshan, Guo, Shuxia, Yu, Kai, Yang, Zhirong, Li, Lishi, Zhang, Yuan, Ji, Linong, Zhan, Siyan · 2015 · Endocrine
  119. DPP-4 Inhibitors in Clinical Practice
    Anna I. Palalau, Abd A. Tahrani, Milan K. Piya, Anthony H Barnett · 2009 · Postgraduate Medicine
  120. Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
    Robert R. Henry, Julio Rosenstock, Douglas K. Logan, Thomas R. Alessi, Kenneth L. Luskey, Michelle A. Baron · 2013 · Diabetes Care
  121. Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus
    Andrew William Hitchings, John R. H. Archer, Shelley A. Srivastava, Emma H. Baker · 2014 · COPD Journal of Chronic Obstructive Pulmonary Disease
  122. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
    Clifford J. Bailey, Caroline Day · 2010 · The British Journal of Diabetes
  123. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
    Lund, S. S, Tarnow, L., Frandsen, M., Nielsen, B. B, Hansen, B. V, Pedersen, O., Parving, H.-H., Vaag, A. A · 2009 · BMJ
  124. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials
    Thomas Hach, John E. Gerich, Afshin Salsali · 2014 · Diabetologie und Stoffwechsel
  125. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study
    Roman Pfister, Richard Cairns, Erland Erdmann, Christian Alfons Schneider · 2011 · International Journal of Cardiology
  126. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial
    Zubin Punthakee, N. Alméras, Jean‐Pierre Després, Gilles R. Dagenais, Sonia Savitri Anand, Dereck L. Hunt, Arya Mitra Sharma, Hyun Suk Jung, Salim Yusuf, Hertzel C. Gerstein · 2014 · Diabetic Medicine
  127. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium–Glucose Cotransporter 2 Inhibitor Treatment
    Heidi Storgaard, Jonatan Ising Bagger, Filip Krag Knop, Tina Vilsbøll, Jørgen Rungby · 2015 · Basic & Clinical Pharmacology & Toxicology
  128. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
    Ueno, Hiroaki, Tsuchimochi, Wakaba, Wang, Hong-Wei, Yamashita, Eiichiro, Tsubouchi, Chikako, Nagamine, Kazuhiro, Sakoda, Hideyuki, Nakazato, Masamitsu · 2015 · Diabetes Therapy
  129. Treating insulin resistance: future prospects
    Clifford J. Bailey · 2007 · Diabetes and Vascular Disease Research
  130. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naïve elderly patients with type 2 diabetes
    S. L. Schwarz, John E. Gerich, Andrea Marcellari, Lisa Jean-Louis, Debaraj Shome Purkayastha, Michelle A. Baron · 2007 · Diabetes Obesity and Metabolism
  131. Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus
    I. W. Campbell · 2005 · International Journal of Clinical Practice
  132. Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD ‐1 and AWARD ‐3 clinical trials
    Matthew D. Reaney, Miao Yu, Mark C Lakshmanan, Valeria Pechtner, Kate Van Brunt · 2015 · Diabetes Obesity and Metabolism
  133. Pharmacokinetics and Pharmacodynamics of Extended‐Release Glipizide GITS Compared with Immediate‐Release Glipizide in Patients with Type II Diabetes Mellitus
    Menger Chung, IONE A. KOURIDES, William J. Canovatchel, Tamara A. Sutfin, Michael Messig, Rochelle L Chaiken · 2002 · The Journal of Clinical Pharmacology
  134. Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
    Kathryn M. Hurren, Nicole R. Pinelli · 2012 · Annals of Pharmacotherapy
  135. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice
    Siri Malmgren, Bo Åhrén · 2015 · Diabetologia
  136. Inhibition of Hdac3 as a Strategy for Developing Novel Diabetes Therapeutics
    Bennett C. Meier, Bridget K. Wagner · 2014 · Epigenomics
  137. A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in J apanese patients with type 2 diabetes
    Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A. O’Neill, Keith D. Kaufman, Samuel S. Engel, Eseng Lai, and the Omarigliptin Study 020 Group · 2017 · Diabetes Obesity and Metabolism
  138. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
    Sanjay Kalra, Rakesh Kumar Sahay, Yashdeep Gupta · 2015 · Indian Journal of Endocrinology and Metabolism
  139. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
    Wolfgang Kothny, Valentina Lukashevich, James Edward Foley, Marc Rendell, Anja Schweizer · 2015 · Diabetologia
  140. Effect of bromocriptine on maturity onset diabetes
    A H Barnett, Catherine Eluned Chapman, K.A.J. Gailer · 1980 · Postgraduate Medical Journal
  141. A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
    L.J. Schmidt, Wolfgang Habacher, T. Augustin, E. Krahulec, Thomas Semlitsch · 2014 · Diabetes Obesity and Metabolism
  142. Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trials
    Bo Åhrén, Jean–François Gautier, Rachele Berria, William Stager, Ronnie Aronson, Clifford J. Bailey · 2014 · Diabetes Obesity and Metabolism
  143. Treatment intensification in patients with type 2 diabetes
    Anthony H Barnett · 2008 · Diabetes Obesity and Metabolism
  144. Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials
    Y. Wang, L. Li, Mengliu Yang, Hongfei Liu, G. Boden, Gangyi Yang · 2011 · Diabetes Obesity and Metabolism
  145. Drug evaluation: Vildagliptin-metformin single-tablet combination
    Abd A. Tahrani, Milan K. Piya, Anthony H Barnett · 2009 · Advances in Therapy
  146. A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome
    Nora E. Straznicky, Mariee T. Grima, Carolina Ika Sari, Nina Eikelis, Gavin William Lambert, Paul J. Nestel, Sofie Karapanagiotidis, Chiew Ying Wong, Katrina Richards, Petra Marušić et al. · 2014 · The Journal of Clinical Endocrinology & Metabolism
  147. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials
    Pavel S Roshanov, Brittany Burns Dennis · 2015 · Diabetes Research and Clinical Practice
  148. Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Wenqiang Liang, Luying Gao, Na Li et al. · 2015 · Hormone and Metabolic Research
  149. Interpreting Adverse Signals in Diabetes Drug Development Programs
    Clifford J. Bailey · 2013 · Diabetes Care
  150. Exenatide once weekly: clinical outcomes and patient satisfaction
    Abd A. Tahrani, Biju Jose, Milan K. Piya, Anthony H Barnett · 2010 · Patient Preference and Adherence
  151. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes
    Alun David Hughes, Chloe M. Park, Katherine March, Emma Coady, Ashraf William Khir, Nish Chaturvedi, Simon Thom · 2012 · International Journal of Cardiology
  152. Empagliflozin for the treatment of type 2 diabetes
    Vidhya R Jahagirdar, Anthony H Barnett · 2014 · Expert Opinion on Pharmacotherapy
  153. A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
    Giuseppe Derosa, Arrigo F.G. Cicero, Ivano Franzetti, Fabrizio Querci, Anna Carbone, Mario N. Piccinni, Angela D’Angelo, Elena Fogari, Pamela Maffioli · 2013 · Diabetes Technology & Therapeutics
  154. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
    Yuhao Huang, Ahmed S. Abdelmoneim, Peter E. Light, Weiyu Qiu, Scot H. Simpson · 2014 · Journal of Diabetes and its Complications
  155. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice?
    Floris A Van de Laar, Peter LBJ Lucassen, J. R. Kemp · 2003 · Diabetes Research and Clinical Practice
  156. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial.
    Rodney F. Carlson, William L. Isley, Francis G. Ogrinc · 1994 · PubMed
  157. Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes
    D. Raccah, Pierre Gourdy, Luc Sagnard, Antonio Ceriello · 2014 · Diabetes/Metabolism Research and Reviews
  158. Repaglinide/Bedtime NPH Insulin Is Comparable to Twice-Daily NPH Insulin
    Araceli Panelo, Jeffrey R. Wing, for the AGEE-1272 Study Group · 2005 · Diabetes Care
  159. Effect of Repaglinide Versus Glyburide on Postprandial Glucose and Insulin Values in Elderly Patients with Type 2 Diabetes
    Graydon S. Meneilly · 2010 · Diabetes Technology & Therapeutics
  160. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
    Aurelia Bellomo Damato, G. Stefanelli, Luigi Laviola · 2010 · Diabetic Medicine
  161. Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus
    J. Rosenstock, K. Truitt, M. Baz-Hecht, D. Ford, B. Tao, H. Chou · 2014 · Hormone and Metabolic Research
  162. Pharmacotherapies to manage diabesity: an update
    Caroline Day, Clifford J. Bailey · 2015